Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

BACKGROUND: In patients with Covid‐19, myocardial injury and increased inflammation are associated with morbidity and mortality. We designed a proof‐of‐concept randomized controlled trial to evaluate whether treatment with canakinumab prevents progressive respiratory failure and worsening cardiac dy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Calvin C, Sahoo, Debasis, Dugar, Siddharth, Prada, Robier Aguillon, Wang, Tom Kai Ming, Abou Hassan, Ossama K, Brennan, Danielle, Culver, Daniel A, Rajendram, Prabalini, Duggal, Abhijit, Lincoff, A Michael, Nissen, Steven E, Menon, Venu, Cremer, Paul C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461303/
https://www.ncbi.nlm.nih.gov/pubmed/32830894
http://dx.doi.org/10.1002/clc.23451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461303/
https://www.ncbi.nlm.nih.gov/pubmed/32830894
http://dx.doi.org/10.1002/clc.23451

Ejemplares similares